VERTEX PHARMACEUTICALS INC / MA Form 8-K August 30, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2011

VERTEX PHARMACEUTICALS INCORPORATED

(Exact name of registrant as specified in its charter)

MASSACHUSETTS

(State or other jurisdiction of incorporation)

000-19319

(Commission File Number)

04-3039129

(IRS Employer Identification No.)

130 Waverly Street

Cambridge, Massachusetts 02139

(Address of principal executive offices) (Zip Code)

(617) 444-6100

(Registrant s telephone number, including area code)

nder any of

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 29, 2011, Kenneth S. Boger, our Senior Vice President and Chief Legal Officer, announced that he will retire from the company on September 23, 2011.

Item 8.01 Other Events.

Effective upon Mr. Kenneth Boger s retirement as our Senior Vice President and Chief Legal Officer on September 23, 2011, he will be succeeded by Ty Howton, who currently is our Chief Compliance Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED

(Registrant)

Date: August 30, 2011 /s/ Valerie L. Andrews Valerie L. Andrews

Vice President and General Counsel

3